BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC).
BNT411 (3 mg/kg; i.v.; 8 times with 4 to 5 days interval) demonstrates antitumor activity in mouse tumor models[1].
References:
[1]. Ugur Sahin, et al. Tlr7 agonist and combinations for cancer treatment. WIPO. WO2023083868. 2023-05-19